4-chloro-2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)pyrido[2,3-d]pyrimidin-7(8H)-one | 911370-50-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 4-chloro-2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)pyrido[2,3-d]pyrimidin-7(8H)-one
• 英文别名: 4-chloro-2-[3-(diethylamino)propylamino]-8-(2,6-difluorophenyl)pyrido[2,3-d]pyrimidin-7-one
• CAS: 911370-50-8
• 化学式: C₂₀H₂₂ClF₂N₅O
• 分子量: 421.877
• InChiKey: PCZYVVBLACUWMS-UHFFFAOYSA-N

物化性质

• 沸点：
  562.0±60.0 °C(Predicted)
• 密度：
  1.344±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  61.4
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-chloro-2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)pyrido[2,3-d]pyrimidin-7(8H)-one 在 四(三苯基膦)钯 三乙基硅烷 、 potassium carbonate 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 0.25h， 生成 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl]-5-fluoro-4-methylbenzoic acid
  参考文献：
  名称：

  WO2007/147103

  摘要：

  公开号：
• 作为产物：
  描述：

  4-chloro-2-methylsulfanyl-8-(2,6-difluoro-phenyl)-8H-pyrido[2,3-d]pyrimidin-7-one 在 三乙胺 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 0.17h， 生成 4-chloro-2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)pyrido[2,3-d]pyrimidin-7(8H)-one
  参考文献：
  名称：

  [EN] 8-PHENYL-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDIN-7-ONES AND THEIR USE AS PHARMACEUTICALS
  [FR] NOUVEAUX COMPOSES

  摘要：

  公开号：

  WO2006104915A3

文献信息

• Novel compounds
  申请人：Callahan F. James

  公开号：US20060235029A1

  公开（公告）日：2006-10-19

  Novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds and compositions, and their use use in therapy as CSBP/RK/p38 kinase inhibitors.

  小说替代2,4,8-三取代8H-吡啶[2,3-d]嘧啶-7-酮含化合物和组合物，并用于治疗作为CSBP / RK / p38激酶抑制剂。
• Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives
  申请人：Boehm C. Jeffrey

  公开号：US20060258687A1

  公开（公告）日：2006-11-16

  The present invention is directed to a novel method of preparing of 2,4,8-trisubstituted pyrido[2,3-d]pyrimidin-7-one pharmacophores of Formula (II) or (IIa) wherein G1 is CH 2 or NH: G2 is CH or nitrogen; Rx is chloro, bromo, iodo, or O—S(O) 2 CF 3 ; R g is a C 1-10 alkyl; m is 0, or an integer having a value of 1, or 2; R 3 is a C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl C 1-10 alkyl, aryl, arylC 1-10 alkyl, heteroaryl, heteroarylC 1-10 alkyl, heterocyclic or a heterocyclylC 1-10 alkyl moiety, and wherein each of these moieties may be optionally substituted. which comprises reacting a compound of the formula: wherein Ry is chloro, bromo, iodo, O—S(O) 2 CF 3 ; and Rg is a C 1-10 alkyl; with a olefin forming reagent in a suitable base to yield a compound of Formula (II), or (IIa) wherein m=0 and oxidizing the sulphur as necessary or desired.

  本发明涉及一种制备2,4,8-三取代吡啶[2,3-d]嘧啶-7-酮药效团的新方法，其化学式为(II)或(IIa)，其中G1为CH2或NH；G2为CH或氮；Rx为氯、溴、碘或O-S(O)2CF3；Rg为C1-10烷基；m为0，或具有值为1或2的整数；R3为C1-10烷基、C3-7环烷基、C3-7环烷基C1-10烷基、芳基、芳基C1-10烷基、杂芳基、杂芳基C1-10烷基、杂环或杂环C1-10烷基基团，其中这些基团可以选择性地被取代。该方法包括将以下化合物与烯烃形成试剂在适当的碱性条件下反应，从而得到化合物(II)或(IIa)，其中m=0，并根据需要或需要氧化硫。化合物的化学式为：其中Ry为氯、溴、碘、O-S(O)2CF3；Rg为C1-10烷基。
• Process for Preparing Pyrido[2,3-d]pyrimidin-7-one and 3,4-Dihydropyrimido[4,5-d]pyrimidin-2(1H)-one Derivatives
  申请人：Callahan James F.

  公开号：US20090048444A1

  公开（公告）日：2009-02-19

  The present invention is directed to a novel method of preparing of 2,4,8-trisubstituted pyrido[2,3-d]pyrimidin-7-one pharmacophores of Formula (II) or (IIa) wherein G1 is CH 2 ; G2 is CH; Rx is chloro, bromo, iodo, or O—S(O) 2 CF 3 ; R g is a C 1-10 alkyl; m is 0, or an integer having a value of 1, or 2; R 3 is a C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl C 1-10 alkyl, aryl, arylC 1-10 alkyl, heteroaryl, heteroarylC 1-10 alkyl, heterocyclic or a heterocyclylC 1-10 alkyl moiety, and wherein each of these moieties may be optionally substituted. which comprises reacting a compound of the formula: wherein Ry is chloro, bromo, iodo, O—S(O) 2 CF 3 ; and Rg is a C 1-10 alkyl; with a olefin forming reagent in a suitable base to yield a compound of Formula (II), or (IIa) wherein m=0 and oxidizing the sulphur as necessary or desired.

  本发明涉及一种制备2,4,8-三取代吡啶[2,3-d]嘧啶-7-酮药物基团的新方法，其化学式为(II)或(IIa)，其中G1为CH2；G2为CH；Rx为氯、溴、碘或O—S(O)2CF3；Rg为C1-10烷基；m为0，或一个值为1或2的整数；R3为C1-10烷基、C3-7环烷基、C3-7环烷基C1-10烷基、芳基、芳基C1-10烷基、杂环芳基、杂环芳基C1-10烷基、杂环或杂环C1-10烷基基团，其中这些基团可以选择性地被取代。该方法包括将以下化合物与烯烃形成试剂在适当的碱性条件下反应，生成式为：其中Ry为氯、溴、碘、O—S(O)2CF3；Rg为C1-10烷基；从而得到化合物(II)或(IIa)，其中m=0，并根据需要或愿望氧化硫。
• Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
  申请人：Callahan Francis James

  公开号：US20080096905A1

  公开（公告）日：2008-04-24

  The present invention is directed to a novel method of preparing of 2,4,8-trisubstituted pyrido[2,3-d]pyrimidin-7-one pharmacophores of Formula (II) wherein G1 is CH 2 or NH: G2 is CH or nitrogen; Rx is chloro, bromo, iodo, or O—S(O) 2 CF 3 ; R g is a C 1-10 alkyl; m is 0, or an integer having a value of 1, or 2; R 3 is a C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl C 1-10 alkyl, aryl, arylC 1-10 alkyl, heteroaryl, heteroarylC 1-10 alkyl, heterocyclic or a heterocyclylC 1-10 alkyl moiety, and wherein each of these moieties may be optionally substituted. which comprises reacting a compound of the formula: wherein Ry is chloro, bromo, iodo, O—S(O) 2 CF 3 ; and Rg is a C 1-10 alkyl; with a olefin forming reagent in a suitable base to yield a compound of Formula (II), wherein m=0 and oxidizing the sulphur as necessary or desired.

  本发明涉及一种制备2,4,8-三取代吡啶[2,3-d]嘧啶-7-酮药效团（式（II））的新方法，其中G1为CH2或NH；G2为CH或氮；Rx为氯、溴、碘或O—S（O）2CF3；Rg为C1-10烷基；m为0或1或2；R3为C1-10烷基、C3-7环烷基、C3-7环烷基C1-10烷基、芳基、芳基C1-10烷基、杂芳基、杂芳基C1-10烷基、杂环或杂环C1-10烷基基团，其中这些基团均可选择性地被取代。该方法包括将下式化合物与烯烃形成试剂在适当碱的作用下反应，得到式（II）的化合物，其中m=0，并根据需要或意愿氧化硫。其中式中Ry为氯、溴、碘或O—S（O）2CF3；Rg为C1-10烷基。
• Novel Compounds
  申请人：Callahan James Francis

  公开号：US20090069318A1

  公开（公告）日：2009-03-12

  Novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.

  小说代替了2,4,8-三取代8H-吡啶[2,3-d]嘧啶-7-酮化合物和组合物，并且它们作为CSBP / RK / p38激酶抑制剂在治疗中使用。